GCP
SIOX

GSA Capital Partners’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

GSA Capital Partners’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-166,806
Closed -$215K – 1958
2021
Q4 		$215K Sell
166,806
-255,342
-60% -$453K 0.03% 1163
2021
Q3 		$916K Buy
422,148
+58,261
+16% +$127K 0.09% 348
2021
Q2 		$993K Buy
363,887
+216,919
+148% +$539K 0.11% 258
2021
Q1 		$384K Sell
146,968
-207,297
-59% -$586K 0.06% 496
2020
Q4 		$985K Buy
354,265
+233,340
+193% +$679K 0.16% 140
2020
Q3 		$559K Buy
120,925
+67,541
+127% +$223K 0.09% 325
2020
Q2 		$151K Buy
53,384
+12,347
+30% +$39.6K 0.08% 411
2020
Q1 		$100K Buy
41,037
+694
+2% +$2.51K 0.03% 898
2019
Q4 		$207K Buy
40,343
+27,482
+214% +$152K 0.02% 1240
2019
Q3 		$83K Sell
12,861
-12,700
-50% -$87.6K 0.01% 1293
2019
Q2 		$159K Buy
25,561
+799
+3% +$6.08K 0.02% 1281
2019
Q1 		$263K Buy
24,762
+5,163
+26% +$51.4K 0.03% 1072
2018
Q4 		$156K Buy
19,599
+3,650
+23% +$52.6K 0.02% 1157
2018
Q3 		$309K Sell
15,949
-2,750
-15% -$50K 0.02% 1308
2018
Q2 		$338K Buy
+18,699
New +$276K 0.02% 1337
2017
Q2 		– Sell
-4,538
Closed -$542K – 2026
2017
Q1 		$542K Buy
+4,538
New +$476K 0.03% 1052
2016
Q3 		– Sell
-1,250
Closed -$128K – 2033
2016
Q2 		$128K Buy
+1,250
New +$125K 0.01% 1652

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

GSA Capital Partners's SIOX Position: Q1 2022 in Review

GSA Capital Partners sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2022, closing a stake of 166,806 shares — an estimated $215K sold.

GSA Capital Partners first reported a position in SIOX in Q2 2016 and held it in 17 quarters. The position peaked at $993K in Q2 2021. 41 funds tracked by Wall St. Rank hold SIOX as of Q1 2022.

  • GSA Capital Partners reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • GSA Capital Partners sold 166,806 Sio Gene Therapies Inc. Common Stock shares in Q1 2022, an estimated $215K.
  • GSA Capital Partners first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2016 and held it in 17 quarters.
  • GSA Capital Partners's Sio Gene Therapies Inc. Common Stock position peaked at $993K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2022.

Based on GSA Capital Partners's 13F filing for Q1 2022, filed 11 May 2022.